Iqvia (IQV) Receives New Coverage from Analysts at Mitsubishi UFJ Financial Group
Stock analysts at Mitsubishi UFJ Financial Group initiated coverage on shares of Iqvia (NYSE:IQV) in a research note issued on Friday. The brokerage set a “neutral” rating and a $112.00 price target on the medical research company’s stock. Mitsubishi UFJ Financial Group’s target price points to a potential upside of 10.38% from the stock’s current price.
A number of other research analysts also recently commented on the stock. TheStreet raised shares of Iqvia from a “c+” rating to a “b” rating in a research report on Wednesday. KeyCorp reiterated a “sector weight” rating and issued a $100.00 target price on shares of Iqvia in a research note on Friday, November 10th. Morgan Stanley lifted their target price on shares of Iqvia from $96.00 to $121.00 and gave the company an “overweight” rating in a research note on Thursday, November 9th. Mizuho cut shares of Iqvia from a “buy” rating to a “neutral” rating and set a $90.00 target price for the company. in a research note on Thursday, November 9th. Finally, SunTrust Banks reiterated a “hold” rating and issued a $114.00 target price on shares of Iqvia in a research note on Friday, November 3rd. Ten analysts have rated the stock with a hold rating, eight have issued a buy rating and one has assigned a strong buy rating to the company’s stock. The company presently has an average rating of “Buy” and an average price target of $105.61.
Iqvia (NYSE IQV) opened at $101.47 on Friday. Iqvia has a 1 year low of $74.73 and a 1 year high of $110.67. The company has a market cap of $21,260.52, a P/E ratio of 23.34, a P/E/G ratio of 1.63 and a beta of 0.61. The company has a current ratio of 1.22, a quick ratio of 1.22 and a debt-to-equity ratio of 1.29.
Iqvia (NYSE:IQV) last announced its quarterly earnings data on Thursday, October 26th. The medical research company reported $1.19 EPS for the quarter, beating the Zacks’ consensus estimate of $1.14 by $0.05. Iqvia had a net margin of 0.58% and a return on equity of 12.60%. The firm had revenue of $2.02 billion for the quarter, compared to the consensus estimate of $2.01 billion. During the same period in the previous year, the firm posted $1.00 earnings per share. The firm’s revenue was up 77.6% on a year-over-year basis. equities analysts anticipate that Iqvia will post 4.62 EPS for the current fiscal year.
In related news, major shareholder Cpp Investment Board Private H sold 7,497,807 shares of the business’s stock in a transaction on Thursday, November 30th. The shares were sold at an average price of $102.00, for a total transaction of $764,776,314.00. The sale was disclosed in a document filed with the SEC, which is available at the SEC website. Also, insider James H. Erlinger III sold 10,000 shares of the business’s stock in a transaction on Wednesday, September 27th. The stock was sold at an average price of $94.52, for a total transaction of $945,200.00. Following the transaction, the insider now directly owns 27,340 shares in the company, valued at approximately $2,584,176.80. The disclosure for this sale can be found here. Insiders sold 16,631,093 shares of company stock valued at $1,640,970,687 over the last 90 days. 6.40% of the stock is owned by corporate insiders.
Iqvia Company Profile
IQVIA Holdings Inc, formerly Quintiles IMS Holdings, Inc, provides integrated information and technology-enabled healthcare services. The Company operates through segments, including Commercial Solutions; Research & Development Solutions, and Integrated Engagement Services. The Commercial Solutions segment offerings include national information offerings, sub-national information offerings, technology solutions, and workflow analytics and consulting services.
Receive News & Ratings for Iqvia Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Iqvia and related companies with MarketBeat.com's FREE daily email newsletter.